enGene Holdings Inc. (ENGN)
(Delayed Data from NSDQ)
$3.68 USD
+0.11 (3.08%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.71 +0.03 (0.82%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENGN 3.68 +0.11(3.08%)
Will ENGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENGN
Best Momentum Stocks to Buy for February 19th
New Strong Buy Stocks for February 19th
ENGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77%
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why
Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks
Other News for ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ENGN Stock News
enGene Announces Board and Leadership Appointments to Support Commercial Readiness | ENGN Stock News
enGene names Matthew Boyd CRO, Jill Buck CDO
Wells Fargo Reaffirms Their Buy Rating on enGene Holdings (ENGN)
FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review ...